Edition:
United States

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

43.52USD
21 Apr 2017
Change (% chg)

$-1.41 (-3.14%)
Prev Close
$44.93
Open
$44.70
Day's High
$44.71
Day's Low
$43.40
Volume
243,272
Avg. Vol
407,270
52-wk High
$85.83
52-wk Low
$41.60

Latest Key Developments (Source: Significant Developments)

Mallinckrodt expands share repurchase plan by $1 bln
Wednesday, 1 Mar 2017 08:00am EST 

Mallinckrodt Plc : Mallinckrodt Plc board expands company's share repurchase plan by $1.0 billion; company announces results of 2017 annual general meeting .Mallinckrodt Plc - authorization is in addition to prior authorizations approved by board.  Full Article

Mallinckrodt Plc adjusted diluted EPS were $1.91 in transition period
Tuesday, 7 Feb 2017 06:00am EST 

Mallinckrodt Plc : Mallinckrodt plc reports transition period results and announces 2017 guidance . 2017 guidance for adjusted diluted earnings per share is $7.40 to $8.00 . Says net sales were $829.9 million in transition period, up 2.3%, or 2.6% on a constant-currency basis . Sees 2017 total mallinckrodt net sales to decrease 2% to 5% . Fy2017 earnings per share view $7.55, revenue view $3.33 billion -- Thomson Reuters I/B/E/S . Says gaap diluted per share results from continuing operations were a loss of $1.67 in transition period .Mallinckrodt plc - adjusted diluted earnings per share were $1.91 in transition period.  Full Article

Mallinckrodt completes sale of its Nuclear Imaging Business to IBA Molecular
Friday, 27 Jan 2017 03:30pm EST 

Mallinckrodt Plc : Mallinckrodt completes sale of its nuclear imaging business to IBA Molecular for approximately $690 million .Entire Nuclear Imaging Business workforce and manufacturing facilities have been transferred to IBAM.  Full Article

Mallinckrodt, Federal Trade Commission resolve Questcor matter
Wednesday, 18 Jan 2017 05:54pm EST 

Mallinckrodt Plc : Mallinckrodt and Federal Trade Commission resolve Questcor matter . Mallinckrodt Plc- currently derives no U.S. revenue from Synacthen depot, and resolution of this matter will not impact Mallinckrodt's net sales .Mallinckrodt Plc - retains rights to continue U.S. Development of Synacthen depot for all other indications, including potential use in treatment of DMD.  Full Article

Mallinckrodt responds to media reports regarding previously disclosed FTC investigation
Wednesday, 18 Jan 2017 03:10pm EST 

Mallinckrodt PLC : Mallinckrodt responds to media reports regarding previously disclosed FTC investigation .Confirms that has entered into a settlement agreement with FTC staff.  Full Article

Mesoblast Ltd says Co and Mallinckrodt enter into agreement
Thursday, 22 Dec 2016 04:54pm EST 

Mesoblast Ltd : Asx alert-Mesoblast and Mallinckrodt enter into agreement-MSB.AX . Mallinckrodt will have exclusive period of up to 9 months to conclude commercial,development agreements for 2 product candidates in all territories outside of Japan and China .Mallinckrodt will purchase approximately 20.04 million of Mesoblast's ordinary shares at a price of A$1.4761 per share.  Full Article

Mallinckrodt Plc reports 2016 fourth quarter results
Tuesday, 29 Nov 2016 06:00am EST 

Mallinckrodt Plc : Q4 gaap earnings per share $1.01 from continuing operations . Mallinckrodt plc reports fiscal 2016 fourth quarter and full-year results . Q4 sales $887.2 million . Q4 adjusted earnings per share $2.04 from continuing operations .Q4 earnings per share view $1.89, revenue view $838.1 million -- Thomson Reuters I/B/E/S.  Full Article

Mallinckrodt will initiate company-sponsored clinical trial of h.p. acthar® gel in treatment of amyotropic lateral sclerosis
Monday, 21 Nov 2016 07:00am EST 

Mallinckrodt Plc : Study is expected to begin in first half of 2017 . Says U.S. Fda has granted co's request for a fast track designation for its acthar investigational new drug (IND) application in patients with ALS .Mallinckrodt will initiate company-sponsored clinical trial of h.p. acthar® gel in treatment of amyotropic lateral sclerosis (als).  Full Article

First patient enrolled in Mallinckrodt phase 4 trial of H.P. Acthar gel
Monday, 14 Nov 2016 07:00am EST 

Mallinckrodt Plc :First patient enrolled in Mallinckrodt phase 4 trial of H.P. Acthar gel for rheumatoid arthritis.  Full Article

Mallinckrodt announces U.S. FDA approval of OFIRMEV IV bag presentation
Tuesday, 8 Nov 2016 07:35am EST 

Mallinckrodt Plc : Mallinckrodt announces U.S. FDA approval of OFIRMEV IV bag presentation .Mallinckrodt Plc says anticipates product availability in q2 of 2017..  Full Article

More From Around the Web

Opioid maker Mallinckrodt agrees to $35 mln U.S. drugs probes settlement

Mallinckrodt Plc, a manufacturer of the generic opioid painkiller oxycodone, said on Monday it had agreed to pay $35 million to resolve U.S. probes into its monitoring and reporting of suspicious orders of controlled substances.